Recent News

• 08.06.2026 - Why speed and scale matter in your discovery pipeline – A scalable compound registration
• 08.06.2026 - Investor panel: What it takes to build a fundable biotech – with Life Science Nation
• 08.05.2026 - Introducing Certara NEXUS: The AI OS for Drug Discovery, Development, and Submission
• 08.04.2026 - Certara Reports Second Quarter 2026 Financial Results
• 08.03.2026 - A Quantitative Systems Pharmacology (QSP) Model for Preclinical to Clinical Translation of ADC Efficacy and Thrombocytopenia
• 08.03.2026 - RsNLME meets MCP: the pharmacometric AI assistant scientists have been asking for
• 07.30.2026 - Go beyond basic validation: Achieve submission-ready datasets with Pinnacle 21 Enterprise
• 07.29.2026 - From Sentence to Simulation: Bringing AI Assistance to Pharmacometrics Modeling
• 07.29.2026 - Advances and Challenges in Model-Informed Precision Dosing of Antimicrobials for Pediatric Patients
• 07.28.2026 - Designing Confident IO Therapies: A Collection of QSP Projects eBook

Recent Filings

• 08.04.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.04.2026 - 8-K Current report
• 08.04.2026 - 8-K Current report
• 07.17.2026 - 3 Initial statement of beneficial ownership of securities
• 07.14.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 07.08.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 06.17.2026 - 8-K Current report
• 06.17.2026 - EX-99.1 EX-99.1
• 06.02.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.02.2026 - 4 Statement of changes in beneficial ownership of securities